Brazil sues China's BYD over 'slavery' conditions on build site
Brazilian prosecutors are suing Chinese electric car giant BYD and two contracting companies for human trafficking and alleged slave labor conditions at a build site, according to legal documents seen by AFP Thursday.
The case concerns 220 Chinese workers found last December in conditions "analogous to slavery" at a BYD plant under construction in Camacari, in the northeastern state of Bahia.
Bahia's regional ministry for works (MPT) said in December it had found "degrading working conditions" at the site being built, expected to be BYD's largest electric car plant outside Asia.
Workers slept without mattresses and, in one case, 31 people had to share a bathroom, it said.
Laborers had "visible signs of skin damage" from working long hours under the sun.
The MPT said it also suspected "forced labor," with illegal clauses in workers' contracts, passports confiscated and the employer withholding as much as 70 percent of their salary. Workers were monitored by armed guards.
After the allegations were made public, BYD's Brazilian subsidiary said it had broken its contract with the Jinjiang contractor responsible for work on the site.
Jinjiang denied the slavery allegation.
The MPT is now seeking 257 million reais ($45.3 million) for "collective moral damages," as well as individual payments for each worker.
The civil suit against BYD, Jinjiang and Tonghe Intelligent Equipment (now Tecmonta) was filed after the companies refused to sign a "conduct adjustment agreement" proposed by Brazilian authorities, the MPT said.
On Thursday, BYD said in a statement it had collaborated with the MPT from the beginning, and "reaffirms its non-negotiable commitment to human and labor rights, guiding its activities by respecting Brazilian legislation and international labor protection standards."
Chinese foreign ministry spokeswoman Mao Ning told reporters Beijing "places great importance on protecting and safeguarding workers' legitimate rights and interests," and requires Chinese companies to "operate in compliance with laws and regulations."
ll/ad/mlr/sst
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Summit Therapeutics stock fell hard recently in response to disappointing clinical trial results. Ivonescimab failed to produced a statistically significant overall survival benefit in the phase 3 Harmoni trial. Ivonescimab has been approved by Chinese regulators, but Summit Therapeutics has a license to sell it outside of China. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. Stock markets have a tendency to sell first and ask questions later. After watching this stock plummet, some bargain-shoppers are wondering if it fell too far. Recent trial results missed the mark the company was hoping for, but the results weren't entirely discouraging. Let's weigh the bad news against the good to see if this stock could be a beaten-down bargain. Summit Therapeutics and its investors have been eagerly anticipating results from the phase 3 Harmoni trial of ivonescimab. It's a bispecific antibody that works like a compination of Keytruda (a PD-1 inhibitor) plus Avastin (a VEGF inhibitor). Summit's stock price rocketed higher in 2024 thanks to Harmoni-2 trial results that showed it outperformed Keytruda at limiting tumor growth in lung cancer patients. Although ivonescimab is already approved in China, it's not for sale in the U.S. and EU, where Summit Therapeutics has a license to sell it. The Harmoni trial enrolled second-line lung cancer patients and treated them with ivonescimab or a placebo plus standard chemo. The treatment reduced the risk of disease progression in terms of tumor growth by 48%, but failed to show a convincing overall survival benefit. Adding ivonescimab to standard chemo reduced patients' risk of death by 21%, but the results fell just outside a 95% confidence interval with a p-value of 0.057. It's highly unlikely the Food and Drug Administration will approve ivonescimab for sale in the U.S. based on the Harmoni trial results. According to Summit, the FDA has been clear about the need for a statistically significant overall survival benefit to support an application. The China-based company that owns ivonescimab, Akeso, recently earned a second approval to market the therapy to lung cancer patients in China. Keytruda sales rose to $29.5 billion last year, and a treatment that can outperform the leader could do even better. Ivonescimab is unlikely to earn approval in the U.S. for patients similar to those enrolled in the Harmoni trial. Given its ability to shrink tumors, though, it's probably just a matter of time before it produces statistically significant overall survival results for an underserved patient population. Tumor responses get attention, but oncologists are far more interested in giving patients a chance for long-term survival. Keytruda's a top seller now because it produced dramatic overall survival results, compared to the standard treatments of its time. The lack of convincing overall survival data so far for ivonescimab severely reduces the odds that it will go on to produce blockbuster sales in the places where Summit Therapeutics has a license to sell it. Despite the obvious challenges ahead, expectations are still sky-high. Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is the only candidate in its pipeline. Despite the lack of options and an uncertain path forward, the stock finished May with a market cap above $13.5 billion. If ivonescimab goes on to produce sales anywhere near Keytruda's, investors who bought Summit Therapeutics at recent prices could reap enormous gains. Unfortunately, the Harmoni trial's failure to produce a convincing overall survival benefit suggests that future sales will be muted, even if the company can get it past the FDA. It's probably best to watch this story play out from a safe distance. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Photo shows crashed Myanmar army chopper in 2022, not 2025
The image of a crashed helicopter on a hillside was shared on Facebook on May 20, 2025. "The result of a grilled dragonfly in Bhamo (20/5 - 1:00 pm)," reads its Burmese-language caption, using local slang for a military helicopter and referring to a city in Myanmar's northern Kachin state. The image circulated after local media said two military helicopters had been shot down, reportedly by the Kachin Independence Army (KIA) in northern Myanmar on May 20 (archived links here and here). According to local media, the KIA resumed attacks on Myanmar's ruling military junta following a quake-rehabilitation truce throughout Kachin State, Northern Shan State and Sagaing Region (archived link). The junta had initially declared a truce in the country's many-sided civil war after a huge quake in late March killed nearly 3,800 and left tens of thousands homeless (archived link). Combat in the civil war is largely confined to the countryside and smaller settlements, although sporadic grenade and gun attacks on police and junta-affiliated targets are regularly reported in the largest city Yangon. The same image circulated in similar posts elsewhere on Facebook here, here and here. But the photo has circulated online since March 2022. A reverse image search on Google found the same photo was used in a report titled "Five injured after a military helicopter crashed on a mountainside in Hakha", which was published by Chinese state news agency Xinhua's Burmese-language edition on March 29, 2022 (archived link). The photo caption reads: "Scene of the military helicopter that crashed in Hakha today (MRTV)". Hakha is the capital of Chin State, nearly 800 km southwest of Bhamo in Kachin State. The report says the military helicopter was carrying exam papers when it crashed on a mountainside "due to a strong wind". The same photo was also used in a report by Myanmar's state-run broadcaster Myanmar International TV on March 29, 2022 (archived link). "Helicopter accident: Tatmadaw helicopter accident near Hakha airport confirmed," reads the report's title, using the military's Burmese name. Other local media also covered the crash here and here (archived here and here). AFP previously debunked a similar claim that shared a photo from the same crash as a helicopter shot down by anti-junta fighters here.
Yahoo
9 minutes ago
- Yahoo
China accuses US of violating trade truce and vows firm retaliation
China criticised the US on Monday for 'seriously violating' a trade truce agreed in Geneva last month, an agreement that temporarily reduced steep tariffs on both sides. The Commerce Ministry denounced Washington's moves to stop the sale of chip design software to China, US warnings against using chips made by China's Huawei, and it attacked the revocation of Chinese student visas. 'We urge the US to work with China to immediately correct relevant wrong practices,' the Commerce Ministry said in a statement. 'If the US insists on its own way and continues to damage China's interests, China will continue to take resolute and forceful measures to safeguard its legitimate rights and interests.' After a breakthrough in early May, Washington lowered tariffs imposed on goods from China from 145% to 30%. Beijing's retaliatory tariffs, meanwhile, were lowered from 125% to 10%. While the deal lasts 90 days, allowing US and Chinese negotiators to reach a more substantial agreement, tensions have since been ratcheting up between the two sides. Related Volkswagen in direct talks with US government regarding tariff deal EU 'strongly regrets' Trump's announcement to double steel and aluminium tariffs to 50% Trump stoked the hostility on Friday, accusing Beijing of violating the truce, without giving details. 'So much for being Mr. NICE GUY," Trump said in a post on Truth Social. US Trade Representative Jamieson Greer later said China had not been removing non-tariff barriers, as per the agreement. He notably criticised Beijing for placing US companies on blacklists and restricting exports of rare earth magnets to the US. Both countries are in a race to develop advanced technologies such as artificial intelligence, with Washington seeking to curb China's access to the most advanced computer chips. 'Instead of reflecting on itself, it [the US] has turned the tables and unreasonably accused China of violating the consensus, which is seriously contrary to the facts,' the Commerce Ministry said in Monday's statement. This Wednesday, the US is set to double its current tariffs on steel and aluminium from 25% to 50%.
